Early versus late endoscopic ultrasound guided celiac plexus neurolysis in unresectable pancreatic cancer patients: A comparative study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202509866770458

Enrollment

Registered

2025-09-17

Start date

2025-07-31

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Early endoscopic ultrasound guided celiac plexus neurolysis

Late endoscopic ultrasound guided celiac plexus neurolysis

Pharmacological treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unresectable pancreatic cancer that had been histologically diagnosed or radiologically consistent. Patients aged =18 years old. Patients with continuous or intermittent visceral pain localized to the upper abdomen, epigastrium and or the mid back or to the right or left hypochondrium, radiating to the back, frequently accentuated by palpitation. Pain score = 4 on a visual analog scale (VAS) of 0 to 10, where no pain = 0 and imaginable maximal pain = 10. Platelet count > 50,000/mm³. White blood cell count > 3,000/mm³. Hemoglobin > 8 g/dL.

Exclusion criteria

Exclusion criteria: Patient's refusal. Resectable pancreatic cancer. Coagulopathy: Platelet count 1.5. Severe comorbidities (e.g., cardiovascular, respiratory disease, uncontrolled DM etc.) Pregnancy or lactation. Psychiatric Disorders. Prior Celiac Plexus Neurolysis (CPN). Known allergy to any of the used drugs.

Design outcomes

Primary

Measure	Time frame
To assess the difference between Visual Analog Scale (VAS) score basal before starting the line of treatment and VAS score every week in the first month and every month for 4 months, in which 0 = no pain and 10 = the worst pain possible. If VAS score is more than 4 after one week the procedure will be considered failed .	—

Secondary

Measure	Time frame
To assess the safety and complications associated with the procedure or related to any of the administered drugs e.g. (anorexia, nausea, general fatigue, insomnia, constipation, diarrhea, hypotension, hematoma, depression, drowsiness).;Determine the impact of (EUS-CPN) on the quality of life and patient satisfaction by quality-of-life questionnaire (QLQ-C30) suggested by the European Organization for Research and Treatment of cancer, at the same time as pain assessment. QLQ-C30 is a 30-item questionnaire composed of multi-item scales in which each item reflects the multidimensionality of the quality of life; a lower scale denotes a better quality of life. ;Assess opioid consumption in these patients using morphine equivalent unit (MEQ).	—

Measure

Time frame

To assess the safety and complications associated with the procedure or related to any of the administered drugs e.g. (anorexia, nausea, general fatigue, insomnia, constipation, diarrhea, hypotension, hematoma, depression, drowsiness).;Determine the impact of (EUS-CPN) on the quality of life and patient satisfaction by quality-of-life questionnaire (QLQ-C30) suggested by the European Organization for Research and Treatment of cancer, at the same time as pain assessment. QLQ-C30 is a 30-item questionnaire composed of multi-item scales in which each item reflects the multidimensionality of the quality of life; a lower scale denotes a better quality of life. ;Assess opioid consumption in these patients using morphine equivalent unit (MEQ).

—

Countries

Egypt

Contacts

Public ContactMerna Maqlad

Researcher

Mernahossammaqlad@mans.edu.eg+0201025815810

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026